BK vs DNLI · P/E 17, rev $20.08B vs $2.11B cap
The Bank of New York Mellon Corporation (BK) versus Denali Therapeutics Inc (DNLI) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported DNLI revenue for 2024-12-31 was $0. Net income was -$422.8M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. DNLI currently screens at market cap $2.11B.
BK currently screens at market cap $94.14B and trailing P/E 17.0. DNLI currently screens at market cap $2.11B.
Not investment advice. Open the BK and DNLI stock pages for the full models.
Not investment advice.